Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 17/20 | 0.66 |
| ▸ | SRC | P12931 | 5/20 | 0.61 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924610 | 0.98 | SYK (0.64) | SYKSRCZAP70CDK2CYP1A1 | |
| SCHEMBL13924612 | 0.88 | SYK (0.61) | SYKSRCZAP70CDK2 | |
| SCHEMBL13924595 | 0.85 | SYK (0.72) | SYKSRCZAP70CDK2PIK3CA | |
| SCHEMBL13924462 | 0.84 | SYK (0.80) | SYKSRCZAP70CDK2CYP1A1 | |
| SCHEMBL13924606 | 0.84 | SYK (0.68) | SYKSRCZAP70CDK2CYP1A1 | |
| SCHEMBL13924608 | 0.82 | SYK (0.66) | SYKSRCZAP70CDK2CYP1A1 | |
| SCHEMBL13924466 | 0.82 | SYK (0.79) | SYKSRCZAP70CDK2 | |
| SCHEMBL13924609 | 0.80 | SYK (0.63) | SYKSRCZAP70CDK2CYP1A1 | |
| SCHEMBL4124957 | 0.80 | SYK (1.00) | SYKSRCZAP70CDK2 | |
| SCHEMBL13924599 | 0.80 | SYK (0.65) | SYKSRCZAP70CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488727-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488727-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-25 | — | — | US | disclosed |
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-25 | — | — | US | disclosed |
| US-7256190-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256190-B2 | Thiazole compounds useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249645-A1 | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE | BTK, AURKC, GSK3B | SYK 5/4885SRC 64/4885ZAP70 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.